Skip to main content

ChEMBL 22 Released


We are pleased to announce the release of ChEMBL 22. This version of the database, prepared on 8th August 2016 contains:

  • 2,043,051 compound records
  • 1,686,695 compounds (of which 1,678,393 have mol files)
  • 14,371,219 activities
  • 1,246,132 assays
  • 11,224 targets
  • 65,213 documents

Data can be downloaded from the ChEMBL ftpsite or viewed via the ChEMBL interface. Please see ChEMBL_22 release notes for full details of all changes in this release.

CHANGES SINCE THE LAST RELEASE

In addition to the regular updates to the Scientific Literature, PubChem, FDA Orange Book and USP Dictionary of USAN and INN Investigational Drug Names this release of ChEMBL also includes the following new data:

Deposited Data Sets:

Two new deposited data sets have been included in ChEMBL_22: the MMV Pathogen Box compound set (http://www.pathogenbox.org) and GSK Tres Cantos Follow-up TB Screening Data (http://dx.doi.org/10.1371/journal.pone.0142293).

Patent Data from BindingDB:

We have worked with the BindingDB team to integrate the bioactivity data that they have extracted from more than 1000 granted US patents published from 2013 onwards (https://www.bindingdb.org/bind/ByPatent.jsp) into ChEMBL. This data is incorporated into ChEMBL in the same way as literature-extracted bioactivity information, but with a new source (SRC_ID = 37, BindingDB Database) and a document type of 'PATENT'. In total this data set provides 99K bioactivity measurements for 68K compounds.

Withdrawn Drugs:

We have compiled a list of drugs that have been withdrawn in one or more countries due to safety or efficacy issues from multiple sources. Where available, the year of withdrawal, the applicable countries/areas and the reasons for the withdrawal are captured. Withdrawal information is shown on the Compound Report Card and a new icon has been added to the availability type section of the  Molecule Features image to denote drugs that have been withdrawn (e.g., https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408).


Tissue Annotation:

We have identified tissues used in assays (e.g., tissues in which measurements were made after in-vivo dosing, isolated tissues on which assays were performed, or tissues from which sub-cellular fractions were prepared) using the Uberon ontology (http://uberon.github.io). A TISSUE_DICTIONARY table has been created, which stores a list of the identified tissues, their corresponding ChEMBL_IDs, names and Uberon IDs. Mappings are also provided to the Experimental Factor Ontology (http://www.ebi.ac.uk/ols/ontologies/efo), Brenda Tissue Ontology (http://www.ebi.ac.uk/ols/ontologies/bto) and CALOHA Ontology (ftp://ftp.nextprot.org/pub/current_release/controlled_vocabularies/caloha.obo). Tissue Report Cards have been created (e.g., https://www.ebi.ac.uk/chembl/tissue/inspect/CHEMBL3638244), providing a mechanism to view all of the assay data associated with a particular tissue. The keyword search now also allows searching by tissue name, Uberon ID, EFO ID, Brenda Tissue ID or CALOHA tissue ID.



Indications for Clinical Candidates:

Indication information has now been extended to cover clinical candidates. This information has been extracted from ClinicalTrials.gov and is included in the 'Browse Drug Indications' view and on Compound Report Cards.

Drug Metabolism Viewer:

An additional section has been added to Compound Report Cards to display drug metabolism schemes (e.g., https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1064). These schemes can be opened in an expanded view by clicking the link above the image. Where known, enzyme information is shown on edges and clicking on an edge of interest will provide additional information about the reaction, including references. Clicking on the nodes allows linking to Compound Report Cards for the metabolites.


Variant Sequences:

For cases where assay data has been measured against a variant protein (e.g., site-directed mutagenesis or drug-resistance studies) we have created a VARIANT_SEQUENCES table to store the variant protein sequence used in the assay (the target for the assay will still be the wild-type protein). Since the exact protein sequence used in an assay is rarely reported in the medicinal chemistry literature, these sequences have been re-created by introducing the specified point mutation into the current UniProt sequence for the target. The resulting sequence is not therefore guaranteed to be the exact sequence used in the assay but provides a more robust way to document the relevant mutation(s) than the current use of residue name and position in most publications and ChEMBL assay descriptions (which quickly becomes obsolete when sequences change). In cases where the reported residue positions could not be reconciled with any UniProt sequence, variant sequence information has not been included in ChEMBL. Further sequences (requiring more curation) will be added in future releases. Assays with variant sequence information available are linked to the VARIANT_SEQUENCES table via the VARIANT_ID column. Please note, this information is not yet displayed on the ChEMBL interface.

We recommend you review the ChEMBL_22 release notes for a comprehensive overview of all updates and changes in ChEMBL 22, including schema changes, and as always, we greatly appreciate the reporting of any omissions or errors.

Keep an eye on the ChEMBL twitter and blog accounts for news and updates.

The ChEMBL Team

Comments

Popular posts from this blog

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

Accessing SureChEMBL data in bulk

It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and  here for a reminder of SureChEMBL is and what it does.  This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for  local (behind the

myChEMBL LaunchPad......Launched!

We are pleased to announce that the latest myChEMBL release (based on ChEMBL_18 ), is available to download . For users not familiar with myChEMBL, the aim of the project is to create an open platform, which combines public domain bioactivity data with open source web, database and cheminformatics technologies. More details about the project can be found in this paper and more details about a recent award it helped pick up can be found here . Like the previous release, once you have installed the myChEMBL virtual machine , you will have access to an Ubuntu linux machine which comes preloaded with the ChEMBL data in a RDKit enabled PostgreSQL database and the original myChEMBL web application. We have added a lot of new features and enhancements to the new myChEMBL release, which include: A local copy the ChEMBL Web Services , which uses the local PostgreSQL database as a backend. A suite of interactive tutorials, created using IPython Notebooks . Topics covered include int

Multi-task neural network on ChEMBL with PyTorch 1.0 and RDKit

  Update: KNIME protocol with the model available thanks to Greg Landrum. Update: New code to train the model and ONNX exported trained models available in github . The use and application of multi-task neural networks is growing rapidly in cheminformatics and drug discovery. Examples can be found in the following publications: - Deep Learning as an Opportunity in VirtualScreening - Massively Multitask Networks for Drug Discovery - Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set But what is a multi-task neural network? In short, it's a kind of neural network architecture that can optimise multiple classification/regression problems at the same time while taking advantage of their shared description. This blogpost gives a great overview of their architecture. All networks in references above implement the hard parameter sharing approach. So, having a set of activities relating targets and molecules we can tra